{
    "Trade/Device Name(s)": [
        "DRI Benzodiazepine Assay"
    ],
    "Submitter Information": "Microgenics Corporation (Thermo Fisher Scientific)",
    "510(k) Number": "K173963",
    "Predicate Device Reference 510(k) Number(s)": [
        "K930529"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JXM"
    ],
    "Summary Letter Date": "February 21, 2018",
    "Summary Letter Received Date": "December 28, 2017",
    "Submission Date": "December 27, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.3170"
    ],
    "Regulation Name(s)": [
        "Benzodiazepine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Benzodiazepines",
        "\u03b1-Hydroxyalprazolam",
        "\u03b1-Hydroxytriazolam",
        "Alprazolam",
        "7-Aminoclonazepam",
        "7-Aminoflunitrazepam",
        "7-Aminonitrazepam",
        "Bromazepam",
        "Chlordiazepoxide",
        "Clobazam",
        "Clonazepam",
        "Clorazepate",
        "Delorazepam",
        "Demoxepam",
        "Desalkylflurazepam",
        "Diazepam",
        "Estazolam",
        "Flunitrazepam",
        "Flurazepam",
        "2-Hydroxyethylflurazepam",
        "Lorazepam",
        "Lorazepam glucuronide",
        "Lormetazepam",
        "Medazepam",
        "Midazolam",
        "Nitrazepam",
        "Norchlordiazepoxide",
        "Nordiazepam",
        "Oxazepam",
        "Oxazepam glucuronide",
        "Prazepam",
        "Temazepam",
        "Temazepam glucuronide",
        "Triazolam"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Clinical chemistry analyzers (e.g., AU680)"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay",
        "Homogeneous enzyme immunoassay",
        "Spectrophotometry (NAD/NADH conversion)"
    ],
    "Methodologies": [
        "Homogeneous enzyme immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for DRI Benzodiazepine Assay using homogeneous enzyme immunoassay for benzodiazepines and metabolites screening in urine on clinical chemistry analyzers",
    "Indications for Use Summary": "Qualitative and/or semi-quantitative determination of benzodiazepines and their metabolites in human urine at a cutoff of 200 ng/mL, as a rapid laboratory screening procedure, with results requiring confirmation by more specific chemical methods.",
    "fda_folder": "Toxicology"
}